Evidence map›Paper›PMID 38654106›Full record

ArticleOncogene2024

Identification of genes that promote PI3K pathway activation and prostate tumour formation.

Jeffrey C Francis, Amy Capper, Alistair G Rust, Klea Ferro, Jian Ning, Wei Yuan, Johann de Bono, Stephen J Pettitt, Amanda Swain

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jeffrey C FrancisDivision of Cancer Biology, Institute of Cancer Research, London, SW3 6JB, UK.ORCID 0000-0001-6646-5749
Amy CapperDivision of Cancer Biology, Institute of Cancer Research, London, SW3 6JB, UK.
Alistair G RustGenomics Facility, Institute of Cancer Research, London, UK.
Klea FerroDivision of Cancer Biology, Institute of Cancer Research, London, SW3 6JB, UK.
Jian NingTumour Modelling Facility, Institute of Cancer Research, London, SW3 6JB, UK.
Wei YuanInstitute of Cancer Research and Royal Marsden Hospital, London, UK.
Johann de BonoInstitute of Cancer Research and Royal Marsden Hospital, London, UK.
Stephen J PettittThe CRUK Gene Function Laboratory, Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, SW3 6JB, UK.ORCID 0000-0003-3313-3857
Amanda SwainDivision of Cancer Biology, Institute of Cancer Research, London, SW3 6JB, UK. amanda.swain@icr.ac.uk.ORCID 0000-0001-8666-1608
Institute of Cancer Research · GB

Funding

Prostate Cancer UK PG13-019
6 · The paper itself

Abstract

We have performed a functional in vivo mutagenesis screen to identify genes that, when altered, cooperate with a heterozygous Pten mutation to promote prostate tumour formation. Two genes, Bzw2 and Eif5a2, which have been implicated in the process of protein translation, were selected for further validation. Using prostate organoid models, we show that either Bzw2 downregulation or EIF5A2 overexpression leads to increased organoid size and in vivo prostate growth. We show that both genes impact the PI3K pathway and drive a sustained increase in phospho-AKT expression, with PTEN protein levels reduced in both models. Mechanistic studies reveal that EIF5A2 is directly implicated in PTEN protein translation. Analysis of patient datasets identified EIF5A2 amplifications in many types of human cancer, including the prostate. Human prostate cancer samples in two independent cohorts showed a correlation between increased levels of EIF5A2 and upregulation of a PI3K pathway gene signature. Consistent with this, organoids with high levels of EIF5A2 were sensitive to AKT inhibitors. Our study identified novel genes that promote prostate cancer formation through upregulation of the PI3K pathway, predicting a strategy to treat patients with genetic aberrations in these genes particularly relevant for EIF5A2 amplified tumours.

Indexed as

Eukaryotic Translation Initiation Factor 5APeptide Initiation FactorsPhosphatidylinositol 3-KinasesProstatic NeoplasmsPTEN PhosphohydrolaseRNA-Binding ProteinsSignal TransductionAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMiceOrganoidsProto-Oncogene Proteins c-aktEukaryotic Translation Initiation Factor 5APeptide Initiation FactorsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanRNA-Binding Proteins

Identifiers

PMID38654106
PMCPMC11164682
OpenAlexW4395043711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.